Compile Data Set for Download or QSAR
Report error Found 221 for UniProtKB: Q66K64
TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633517(US11807606, Compound 1)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633518(US11807606, Compound 2)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633519(US11807606, Compound 3)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633520(US11807606, Compound 4)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633521(US11807606, Compound 5)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633522(US11807606, Compound 6)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633523(US11807606, Compound 7)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633524(US11807606, Compound 8)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633525(US11807606, Compound 9)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633526(US11807606, Compound 10)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633527(US11807606, Compound 11)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633528(US11807606, Compound 12)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633529(US11807606, Compound 13)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633530(US11807606, Compound 14)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633531(US11807606, Compound 15)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633532(US11807606, Compound 16)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633533(US11807606, Compound 17)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633534(US11807606, Compound 18)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633535(US11807606, Compound 19)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633536(US11807606, Compound 20)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633537(US11807606, Compound 21)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633538(US11807606, Compound 22)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633539(US11807606, Compound 23)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633540(US11807606, Compound 24)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633541(US11807606, Compound 25)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633542(US11807606, Compound 26)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633543(US11807606, Compound 27)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633544(US11807606, Compound 28)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633545(US11807606, Compound 29)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633546(US11807606, Compound 30)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633547(US11807606, Compound 31 | US11807606, Compound 44)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633548(US11807606, Compound 32)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633549(US11807606, Compound 33)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633550(US11807606, Compound 34)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633551(US11807606, Compound 35)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633552(US11807606, Compound 36)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633553(US11807606, Compound 37)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633554(US11807606, Compound 38)
Affinity DataEC50:  5.50E+3nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633555(US11807606, Compound 39)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633556(US11807606, Compound 40)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633557(US11807606, Compound 41)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633558(US11807606, Compound 42)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633559(US11807606, Compound 43)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633547(US11807606, Compound 31 | US11807606, Compound 44)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetDDB1- and CUL4-associated factor 15(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM633561(US11807606, Compound 45)
Affinity DataEC50: >1.00E+4nMAssay Description:Increasing concentrations of compounds were added to pre-mixed biotinylated DCAF15 at 200 nM, Bodipy-FL-labelled RRM2 domain in RBM39 at 200 nM, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetRNA-binding protein 39 [150-331]/DDB1- and CUL4-associated factor 15(Human)
Recursion Pharmaceuticals

US Patent
LigandPNGBDBM659427(US20240092770, Compound 2)
Affinity DataEC50:  1.03E+3nMAssay Description:A TR-FRET assay was used to assess the effect of compounds disclosed herein on the interaction between RBM39 and the DCAF15 complex. Test compounds w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetRNA-binding protein 39 [150-331]/DDB1- and CUL4-associated factor 15(Human)
Recursion Pharmaceuticals

US Patent
LigandPNGBDBM659428(US20240092770, Compound 3)
Affinity DataEC50:  429nMAssay Description:A TR-FRET assay was used to assess the effect of compounds disclosed herein on the interaction between RBM39 and the DCAF15 complex. Test compounds w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetRNA-binding protein 39 [150-331]/DDB1- and CUL4-associated factor 15(Human)
Recursion Pharmaceuticals

US Patent
LigandPNGBDBM659429(US20240092770, Compound 7)
Affinity DataEC50:  106nMAssay Description:A TR-FRET assay was used to assess the effect of compounds disclosed herein on the interaction between RBM39 and the DCAF15 complex. Test compounds w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetRNA-binding protein 39 [150-331]/DDB1- and CUL4-associated factor 15(Human)
Recursion Pharmaceuticals

US Patent
LigandPNGBDBM659430(US20240092770, Compound 8)
Affinity DataEC50:  787nMAssay Description:A TR-FRET assay was used to assess the effect of compounds disclosed herein on the interaction between RBM39 and the DCAF15 complex. Test compounds w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetRNA-binding protein 39 [150-331]/DDB1- and CUL4-associated factor 15(Human)
Recursion Pharmaceuticals

US Patent
LigandPNGBDBM659431(US20240092770, Compound 9)
Affinity DataEC50:  436nMAssay Description:A TR-FRET assay was used to assess the effect of compounds disclosed herein on the interaction between RBM39 and the DCAF15 complex. Test compounds w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

Displayed 1 to 50 (of 221 total ) | Next | Last >>
Jump to: